P1.27. BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Lucia Robado de Lope
Meta Tag
Speaker Lucia Robado de Lope
Topic Early-Stage NSCLC: Innovation & New Technology
BRAF mutations
neoadjuvant chemo-immunotherapy
non-small-cell lung cancer
tumor molecular alterations
pathological complete response
next-generation sequencing techniques
NADIM and NADIMII clinical trials
prognostic factor
treatment response
Powered By